Unique ID issued by UMIN | UMIN000048036 |
---|---|
Receipt number | R000054747 |
Scientific Title | Prospective Registry Observational Study of Carbon Ion Radiation Therapy in Mucosal Malignant Melanoma of the Head and Neck |
Date of disclosure of the study information | 2022/06/13 |
Last modified on | 2023/02/17 16:32:01 |
Prospective Registry Observational Study of Carbon Ion Radiation Therapy in Mucosal Malignant Melanoma of the Head and Neck
Prospective Registry Observational Study of Carbon Ion Radiation Therapy in Mucosal Malignant Melanoma of the Head and Neck
Prospective Registry Observational Study of Carbon Ion Radiation Therapy in Mucosal Malignant Melanoma of the Head and Neck
Prospective Registry Observational Study of Carbon Ion Radiation Therapy in Mucosal Malignant Melanoma of the Head and Neck
Japan |
Mucosal Malignant Melanoma of the Head and Neck
Radiology |
Malignancy
NO
To determine the efficacy of an acceptable treatment approach that allows the use of immune checkpoint inhibitors after carbon ion radiotherapy for mucosal malignant melanoma of the head and neck
Efficacy
The overall survival rate will be evaluated between two groups, one with and the other without immune checkpoint inhibitors administered within the usual care after carbon ion radiotherapy.
Observational
16 | years-old | <= |
Not applicable |
Male and Female
1) Patients with histologically proven mucosal malignant melanoma of the head and neck region.
2) Patients with N0M0 (TNM classification, 8th edition).
3) Patients with measurable lesions.
4) Patients who are scheduled to receive heavy particle radiotherapy.
5) Patients who are 16 years of age or older.
6) Patients whose Performance Status (PS) is 0-2.
7) Patients who have been informed of the name and condition of their disease and have the capacity to consent.
(For minors, the consent of a legal guardian is required.)
1) Patients with a history of radiation therapy to the area to be treated.
2) Patients with active and refractory infection at the irradiated site.
3) Patients with serious complications (uncontrolled diabetes mellitus, myocardial infarction requiring emergency treatment, unstable angina, uncontrolled arrhythmia, bleeding tendency due to untreated bleeding disorder, collagen disease requiring steroid administration, etc.)
4) Patients with active multiple cancers (simultaneous multiple cancers and iatrogenic multiple cancers with a disease-free interval of 5 years or less). However, lesions equivalent to intraepithelial or intramucosal carcinoma that are considered curable by local treatment are not included in the active overlapping cancers.
5) Other patients who are deemed medically, psychologically, or due to other factors to be inappropriate by the physician in charge.
25
1st name | Tatsuya |
Middle name | |
Last name | Ohno |
Gunma University Graduate School of Medicine
Department of Radiation Oncology
3718511
3-39-22 Showa-machi, Maebashi, Gunma
027-220-8383
tohno@gunma-u.ac.jp
1st name | Atsushi |
Middle name | |
Last name | Musha |
Gunma University
Heavy Ion Medical Center
3718511
3-39-22 Showa-machi, Maebashi, Gunma
027-220-8378
musha@gunma-u.ac.jp
Gunma University
none
Other
Gunma University Hospital Clinical Research Review Board
3-39-15 Showa-machi, Maebashi, Gunma
027-220-8740
gunmaciru-office@umin.ac.jp
NO
2022 | Year | 06 | Month | 13 | Day |
Unpublished
Open public recruiting
2022 | Year | 06 | Month | 07 | Day |
2022 | Year | 05 | Month | 19 | Day |
2022 | Year | 06 | Month | 13 | Day |
2027 | Year | 03 | Month | 31 | Day |
none
2022 | Year | 06 | Month | 12 | Day |
2023 | Year | 02 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054747